• News
  • Finance

Novartis Advances Most in Three Years on Heart-Failure Study

Sept. 1 (Bloomberg) -- Novartis AG gained the most in almost three years after a study showed that an experimental heart failure drug kept more patients from dying or being hospitalized than the standard therapy, a result that may transform treatment of the disease that afflicts 26 million people worldwide.

To continue reading, subscribe now
log in to your account
User Response
0 UserComments
Subscribe Today!